<DOC>
	<DOCNO>NCT00000392</DOCNO>
	<brief_summary>To evaluate chemical efficacy safety intranasally administer peptide T neurocognitive function HIV seropositive individual . Previous study show treatment peptide T result cognitive improvement HIV-infected patient . Patients randomize receive either peptide T placebo first 6 month . All patient receive open-label peptide T approximately 6 additional month . Neuropsychologic test use determine drug effect .</brief_summary>
	<brief_title>Phase II Study Efficacy Peptide T HIV-Positive Individuals With Cognitive Impairment .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Patients must : 1 . Cognitive dysfunction neuropsychological testing . 2 . HIV antibody positivity . 3 . Expected survival 6 month . 4 . EITHER use antiretroviral within past 4 week OR use approve regimen AZT , ddI , ddC . 5 . Medically stable EKG urinalysis . 6 . Given informed , write consent participate . Allowed : 1 . Inhaled aerosolized pentamidine Pneumocystis carinii pneumonia prophylaxis , dapsone , cotrimoxazole , topical antifungal agent , nystatin ketoconazole , acyclovir . 2 . Amitriptyline ( 50 mg/day ) equivalent dose another antidepressant relief peripheral neuropathy expect remain unchanged throughout first 6 month study . Abstinence agree use barrier method birth control / contraception study Negative pregnancy test within 30 day study entry Bilirubin &lt; = 3 CD4 ( Must &lt; = 500 cells/mm3 patient without noncognitive HIVrelated symptom . CD4 count &gt; 500 cells/mm3 allow patient ( noncognitive ) HIVrelated symptom . ( 0 100 200 300 400 500 600 700 800 plus . ) Creatinine &lt; = 1.5 mg/dl Granulocytes &gt; = 750 Hemoglobin &gt; 8 g/dl ( No two transfusion per month permit . ) Other Lab Values Prothrombin time &gt; 70 percent control . Platelet Count &gt; = 75000 /mm3 SGOT ( AST ) &lt; 5 x ULN ( ULN = upper limit normal ) . Patients follow exclude : 1 . History mental retardation learn disability . 2 . Evidence current DSMIIIR Axis I disorder within 3 month prior study entry past history psychotic disorder bipolar mania . 3 . History neurologic disorder secondary HIV infection ( e.g. , head trauma require medical observation hospitalization , seizure disorder ) . Patients follow symptoms condition exclude : 1 . Kaposi 's sarcoma malignancy likely require chemotherapy first 6 month study . 2 . Serious underlie medical problem may complicate interpretation treatment result , include unstable diabetes mellitus , severe arteriosclerotic heart disease , uncontrolled hypertension , hepatic renal failure . 3 . NonHIV related condition likely interfere interpretation neuropsychologic test result . 4 . Inability participate neuropsychologic test unable comply intranasal study medication administration . Excluded within 4 week prior study entry : 1 . Antiretrovirals except allow Patient Inclusion Criteria . 2 . Psychoactive agent ( e.g. , benzodiazepine , antidepressant , antipsychotic , amphetamine ) Excluded within 8 week prior study entry : Longacting psychoactive agent ( e.g. , Prozac ) . Active alcohol abuse past 3 month , abuse judge investigator likely interfere analysis neuropsychologic function . Abuse cocaine , marijuana , heroin opiate ( include methadone ) , barbiturates , amphetamine substance within past 3 month , judge investigator likely interfere analysis neuropsychologic test . Positive pregnancy test within 30 day study entry No abstinence agreement use barrier method birth control / contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>